These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33508648)

  • 21. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
    Corsten CEA; Huygens SA; Versteegh MM; Wokke BHA; Smets I; Smolders J
    Mult Scler Relat Disord; 2023 Dec; 80():105100. PubMed ID: 37944195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
    J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
    Kalincik T; Diouf I; Sharmin S; Malpas C; Spelman T; Horakova D; Havrdova EK; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Jokubaitis V; van der Walt A; Grand'Maison F; Sola P; Ferraro D; Shaygannejad V; Alroughani R; Hupperts R; Terzi M; Boz C; Lechner-Scott J; Pucci E; Van Pesch V; Granella F; Bergamaschi R; Spitaleri D; Slee M; Vucic S; Ampapa R; McCombe P; Ramo-Tello C; Prevost J; Olascoaga J; Cristiano E; Barnett M; Saladino ML; Sanchez-Menoyo JL; Hodgkinson S; Rozsa C; Hughes S; Moore F; Shaw C; Butler E; Skibina O; Gray O; Kermode A; Csepany T; Singhal B; Shuey N; Piroska I; Taylor B; Simo M; Sirbu CA; Sas A; Butzkueven H;
    Neurology; 2021 Feb; 96(5):e783-e797. PubMed ID: 33372028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
    Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada.
    Nakhaipour HR; Vudumula U; Khurana V; Sébire G; Mah JK; Pohl D; Schecter R; Adlard N
    J Med Econ; 2020 Dec; 23(12):1525-1533. PubMed ID: 33079578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disability progression
    von Wyl V; Benkert P; Moser A; Lorscheider J; Décard B; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö
    Mult Scler; 2021 Mar; 27(3):439-448. PubMed ID: 32463336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
    Braune S; Lang M; Bergmann A;
    J Neurol; 2016 Feb; 263(2):327-333. PubMed ID: 26645389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
    Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
    CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurometabolic changes in multiple sclerosis: Fingolimod versus beta interferon or glatiramer acetate therapy.
    Al-Iedani O; Lea R; Ribbons K; Ramadan S; Lechner-Scott J
    J Neuroimaging; 2022 Nov; 32(6):1109-1120. PubMed ID: 35922880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of fingolimod after switching from interferon β-1a in an adolescent with multiple sclerosis: case report.
    Amidei A; Siciliano G; Pasquali L
    Neurol Sci; 2021 May; 42(Suppl 1):5-7. PubMed ID: 33723709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of glatiramer acetate, IFNβ-1a, fingolimod, and dimethyl fumarate on the expression of T-bet, IFN-γ, and MEG3 in PBMC of RRMS patients.
    Dabbaghi R; Safaralizadeh R; Rahmani S; Barpour N; Hosseinpourfeizi M; Rajabi A; Baradaran B
    BMC Res Notes; 2023 Oct; 16(1):273. PubMed ID: 37845751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.
    Koda T; Namba A; Nakatsuji Y; Niino M; Miyazaki Y; Sugimoto T; Kinoshita M; Takata K; Yamashita K; Shimizu M; Fukazawa T; Kumanogoh A; Mochizuki H; Okuno T
    PLoS One; 2018; 13(3):e0193986. PubMed ID: 29518148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
    J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies.
    Haas J; Jeffery D; Silva D; Meier DP; Meinert R; Cohen J; Hartung HP
    Mult Scler Relat Disord; 2019 Nov; 36():101335. PubMed ID: 31557679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
    Kapica-Topczewska K; Tarasiuk J; Collin F; Brola W; Chorąży M; Czarnowska A; Kwaśniewski M; Bartosik-Psujek H; Adamczyk-Sowa M; Kochanowicz J; Kułakowska A
    PLoS One; 2019; 14(10):e0223863. PubMed ID: 31647829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.